Severe cutaneous adverse reactions associated with immune checkpoint inhibitors therapy and anti-VEGF combination therapy: a real-world study of the FDA adverse event reporting system

CONCLUSIONS: Treatment with joint therapy of ICIs and anti-VEGF agents may cause severe cutaneous adverse events. It is vital to identify ICI-related SCARs early, and to manage them appropriately.PMID:37622438 | DOI:10.1080/14740338.2023.2251381

Source: Expert Opinion on Drug Safety - August 25, 2023 Category: Drugs & Pharmacology Authors: Chunlei Li Zhengjun Li Qing Sun Yanxiao Xiang Anchang Liu Source Type: research